- Home
- WBX vs JSPR Comparison
WBX vs JSPR Comparison
Compare WBX & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WBX | JSPR |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.2M | 26.3M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | WBX | JSPR |
|---|---|---|
| Price | $2.73 | $0.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | $4.75 | ★ $15.50 |
| AVG Volume (30 Days) | 12.7K | ★ 339.9K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.10 | N/A |
| Revenue Next Year | $94.11 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.30 | $0.32 |
| 52 Week High | $7.83 | $2.69 |
Technical Indicators
Market Signals| Indicator | WBX | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 39.89 | 47.76 |
| Support Level | $2.64 | $0.56 |
| Resistance Level | $3.12 | $0.67 |
| Average True Range (ATR) | 0.17 | 0.05 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 0.00 | 48.41 |
Price Performance
Historical ComparisonAbout WBX Wallbox N.V.
Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments: Europe, the Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.